Hyperthermia Blog

What's New, What's News, What's Happening

enfrdehija

The importance of Peer Review and Socks

In today’s e-commerce economy, the customer review takes on an important role. We can instantly access the opinion of a community of our peers with similar product interests. A simple purchase, like socks, still provides us with a litany of customer satisfaction reviews to help us make positive purchasing decisions. As a sock manufacturer, I would be free to make almost any claim, like durability, comfort or value, that I wish. We rely on the unbiased consumer review to be the gatekeeper of manufacturer claims. This form of Peer Review is now the standard in online purchasing, a resource unavailable ten years ago.

peer review socks

There is no Amazon.com ratings to help us maneuver through these cancer treatment choices!

Peer Review, the evaluation of scientific, academic, or professional work by others working in the same field, is the gatekeeper of the medical device market. Data is often missinterpreted, so we are reliant on the power of Peer Review to verify substantive claims of efficacy. In the US, we also have the addition of the FDA, which strictly monitors all manufacturer claims. These regulations prevent overstatement of the capabilities and/or theoretical benefits of the device. Without these restrictions, patients can be taken advantage of by ancedotal or unproven claims.  In the case of cancer, misleading information puts lives at risk. There is no Amazon.com ratings to help us maneuver through these cancer treatment choices.

When asked if any of the data presented had been through the peer review process?
The Answer was NO.

At this year’s ESHO, a fellow device manufacturer and show sponsor, gave an informative presentation on their product line. The company is very vocal about their claims, has published extensively, written books on their process, and presented years of collected findings on their hyperthermia devices. At the conclusion of their presentation the moderator thanked them for the presentation and asked if any of the data presented had been through the peer review process? It had not. This does not mean that the data presented was falsified or inaccurate, simply that it had not been substantiated by peers in the field.

Pyrexar Medical is strongly committed to the peer review process which is essential, if we have any chance of moving hyperthermia to the forefront of cancer care. We cannot afford to make isolated claims about our products without engaging the research community in the process. Please continue to encourage all manufacturers to adhere to the standards and best practices on our industry

Kirloskar Group Brings Hyperthermia Cancer Treatment to India

Pyrexar is proud to welcome Kirloskar Technologies to its distributor network. Kirloskar Technologies, popularly known as KTPL, is part of the 100 year old, multi-billion dollar conglomerate, the Kirloskar Group.

KTPL logo 250pxKirloskar has been a successful healthcare enterprise for more than two decades, offering a multi-disciplinary product portfolio catering to the fields of Cardiac Surgery, Interventional Radiology, Interventional Cardiology, Neurosurgery, Nuclear Medicine, Oncology, Radiography, Vascular Surgery, Minimal Invasive Surgery and Plastic & Reconstructive Surgery. 

According to cancerindex.org, more than 1 million people were diagnosed with cancer in India in 2012. Cancer death rates stand at 680,000 each year. The National Cancer Registry puts breast cancer as the most common cancer for women in India, with cervical cancer in second. It is estimated that for every two women newly diagnosed with breast cancer, one dies. Every 8 minutes, a woman dies of cervical cancer. The good news is that hyperthermia is a highly effective adjunct treatment of both breast cancer and cervical cancers.

Geography of Cancer India

India represents a significant expansion into Asia for Pyrexar. India accounts for one-sixth of the world population, 10 times greater than the population of the United states.  Kirloskar believes that Pyrexar’s hyperthermia line is an excellent companion to their radiotherapy product offering and the therapy will play an important role treatment of cancer in the country. There are some real advocates for hyperthermia in the region. We believe these influencers can help bring awareness and acceptance of the technology to cancers centers throughout India.

Recent visit to China

dalian port cityHealthcare spending in China has been increasing over the past few years and China is now the second largest healthcare market in the world. Pyrexar has been represented in China by our trading partner Orientech Dalian for the last 10 years.  Ever since the name and address change from BSD Medical to Pyrexar, we have been working with the Chinese regulatory agencies to re-register the product for export to the country.  Bureaucracy can take its toll on market presence, especially in the growing field of hyperthermia.

orientech ansteelMrs. Wang, President (Orientech); Bob Depalma, VP Regulatory (Pyrexar); Dr. Wu Dengbin, VP Oncology Ansteel; Mark Falkowski, CEO (Pyrexar); Dr. Zhou Tong (Ansteel); Dr. Zhu Xu (Ansteel)

So we took a trip to China to review our regulatory progress and meet with potential customers for our hyperthermia products. As we have experienced in the past, Orientech is a very generous host, treating us very well on each leg of our journey.  After some internal discussions with our distributors, we believe we have a direction to alleviate the regulatory blocks so products will again be available in China.

Orientech invited us to present our hyperthermia line to key prospects in the area. The first stop was the Ansteel Group Hospital, a large facility in the Tiedong District of Anshan in the Liaoning Province. The Ansteel Group facility houses centers for Cancer, Genetic Detection, Immunotherapy, and Radiation Oncology. Our next stop was Dalian Municipal Central Hospital in the Shahekou District of  Dalian in the Liaoning Province.  Dalian Municipal has received many accolades including “top 20 best service hospitals” and “most reliable hospital in the province”. ansteel immunotherapy

After successfully met presentations, not only were the hospitals very excited and receptive about adding hyperthermia to their cancer treatment services, but preferred the newly updated, top of the line, Image Guided Thermal System, the BSD-2000 3D/MR. According to Mrs. Wang, president of Oreintech, there are more than half a dozen hospitals in region looking at the new MRI based system.   Now I feel a bit embarrassed teasing the new product without supporting product information.  Our first commercial installation of the newly updated product is being signed off this week in Munich, Germany, and we will bring you more details very soon.

Saudi Cancer Foundation brings Hyperthermia Awareness to KSA

Pyrexar was invited to present its hyperthermia line to the leading oncologists in the KSA (Kingdom of Saudi Arabia) last week. The meeting was organized by the Saudi Cancer Foundation (SCF) with cooperation from the Al Afandi Medical Group. The SCF was formed to increase cancer awareness and inform the public about the importance of early detection and advancements in cancer treatment. 

Even though cancer incidence is lower than world average in Saudi Arabia, colorectal cancer, prostate cancer, non-hodgkins lymphoma and lung cancer ranks highest in incidence for the population of 27 million. The country is looking to improve healthcare outcomes and is exploring the benefits of hyperthermia in the treatment of cancer.

saudi arbia map
Attending via Skype was Mark Falkowski, CEO of Pyrexar Medical. Mr. Falkowski presented Pyrexar's recent achievements in the advancement of radio frequency delivered hyperthermia. RF phased array hyperthermia is well established in its ability to deliver power both to superficial (surface cancers within 4 cm) and deep regional (any depth in the body), to heat tissue to targeted temperatures of 43˚C. A recent study by the University of Amsterdam, “A comparison of the heating characteristics of capacitive and radiative superficial hyperthermia, (Kok and Crezee, 2017) proved that radiative RF, the method used in Pyrexar Medical's BSD-500, is far superior to systems that use capacitive heating methods (i.e. Oncotherm, Celcius 42).

Also presenting was Dr. Mark Hurwitz of Thomas Jefferson University Hospital. Dr. Hurwitz is a widely recognized leader in the fields of thermal medicine and genitourinary oncology, and previously served as Director of Regional Program Development for the Department of Radiation Oncology at the Dana-Farber/Brigham and Women’s Cancer Center, A long time clinician, researcher and hyperthermia expert, Dr. Hurwitz presented clinical results and discussed hyperthermia’s role in the treatment of cancer.  A special thanks to the Al Afandi Medical group, Pyrexar's representative in the region, as well as Mira Sirotic of Alltranix in the organization of the event. 

Pyrexar Medical has completed product registration and regulatory requirements with the KSA and is preparing to place hyperthermia systems in the kingdom.

Hyperthermia Takes Center Stage in South Korea

Hyperthermia, well known as a radiosensitizer for cancer treatment, has found its way into South Korea’s leading cancer centers. The country, with a population over 50 million, has the third highest cancer rate among women and ranks 8th in the world overall. In addition to treating cancers of the pelvic region with the Pyrexar BSD-2000 Deep Regional Hyperthermia system, physicians have also found profound value in hyperthermia as a palliative treatment. Prescribing hyperthermia to relieve cancer-related pain and increase patient mobility is being used in convalescent centers throughout the country.

hanbeam sk 062017(left to right) James Kim, Bob DePalma, Brian Bay, Mark Falkowski

The BSD-2000 units are getting quite a workout in centers throughout South Koreas. Some facilities are reporting 8 to 10 treatments a day, every day, generating an estimated 200 patient treatments a month.

During a recent trip to Asia, Pyrexar CEO, Mark Falkowski met with Hanbeam Technologies president, Brian Bay and his team in Seoul, Korea. Hanbeam is a Pyrexar sales leader and has placed 11 BSD-2000 Deep Regional units in the country in the last 12 months. Currently Hanbeam is waiting regulatory approval from the KFDA to import the BSD-500 Superficial Hyperthermia system into the region.

Hanbeam continues to promote hyperthermia with a major presentation in Seoul this month, inviting well-known hyperthermia expert Dr. Jacoba van der Zee from Erasmus University in The Netherlands. Dr. van der zee has authored many clinical papers and several landmark hyperthermia studies. Her extensive clinical experience in treating a range of cancers using hyperthermia makes her a well-spring of knowledge in a country that is embracing the technology.

STM 2017 Highlights

This years STM (Society of Thermal Medicine) conference was a great success.  The 3 day event was held at the beautiful CasaMagna Marriot Resort in Cancun, Mexico.  The society strives to promote new discoveries in thermal biology, physics/engineering and medicine.  Each year they come together to present their ideas in this forum.

STM 2017 Booth

Highlights

  1. Dr. Rolf Issels, Ludwig-Maximilians-University of Munich, included an update on the long term survival benefit of adding hyperthermia to chemotherapy for soft tissue sarcoma in the Phase III randomized clinical trial.  Data demonstrates a more than doubling the overall survival time. Chemotherapy averaging 6.2 years vs. 15.4 years when adding hyperthermia.  Treatments were performed using the Pyrexar BSD-2000. 

  2. Dr. Jacoba Van der Zee, Erasmus University,  gave a very good talk reviewing 55 hyperthermia randomized trials including 5,099 patients showing the significant effectiveness of HT.  Significant benefit was found in 19 of 27 trials when adding hyperthermia to radiation therapy, 9 of 11 trials when adding HT to chemotherapy, and in 7 of 10 trials by adding HT to both radiation plus chemotherapy.  Concluding, “These results indicate that hyperthermia is a universal and effective modifier of radiotherapy and/or chemotherapy in malignant tumors.”

  3. Dr. Elizabeth Repasky, Roswell Cancer Center, presented a plenary lecture describing the many ways that elevated temperature and physical stresses can stimulate immune responses.  

  4. Dr. Hana Trefna, Chalmers University of Technology, presented efforts to release in this summer a new ESHO QA guideline to support the growing interest and application of interstitially applied hyperthermia with Brachytherapy.

  5. Dr. Ruediger Wessalowski, University of Dusseldorf, reported the success in treating pediatric ovarian germ cell tumors with hyperthermia and chemotherapy using the Pyrexar BSD-2000 system.  This study included 22 patients.  The overall survival in this patient population with an unfavorable prognosis was 71% (95% CI 46-86).  This concluded: “A multi-modality therapy including regional hyperthermia according to the Hyper-PEI protocol has led to long-term remission in the majority of patients with advanced refractory or recurrent ovarian germ cell tumors.”  

  6. Dr. Niloy Datta, Kantonspital Aarau AG, presented a systemic review and meta-analysis of HT and RT in locally recurrent breast cancer which was also published in 2016.  This review report included 34 clinical studies that included 2110 patients.  The conclusion of the met-analysis is “Thermoradiotherpay (HTRT) enhances the likelihood of complete response rates in locally recurrent breast carcinomas (LRBTCs) over radiation therapy alone by 22% with minimal acute and late morbidities.  For even those previously irradiated, re-irradiation with hyperthermia provides a loco-regional control in two-thirds of the patients.  HTRT could therefore be considered as an effective and safe palliative treatment option for LRBCs.”  

  7. Dr. James Snider, University of Maryland, reported treatments for 87 patients treated with the Pyrexar BSD-500.  Of this group 3 patients were treated by a pencil beam scanning proton therapy method showing the feasibility of combining hyperthermia with proton therapy.

  8. Dr. Arpit Chabra, University of Maryland, reported on the use of the Pyrexar BSD-500 hyperthermia as an external thermal therapy (ETT) method with external beam radiotherapy (EBRT) in treating non-melanoma skin cancers on 6 patients.   The conclusion stated: “This data tends to support strong consideration of using ETT concurrently with EBRT in this setting. “

  9. Gerard Van Rhoon, Phd, Erasmus MC Cancer Institute, was presented with the 28th J. Eugene Robinson award presented annually to an investigator who has made outstanding contributions to the field of hyperthermic oncology.
     
  10. Mark W. Dewhirst, Phd, Duke University, was presented with the George M Hahn award presented every other year to an investigator whose research has contributed in a significant way to new clinical applications in thermal therapy. 

Thanks for STM president Robert Ivkov, Johns Hopkins University School of Medicine, and team for putting on an amazing event.

Oncothermia "No Results Found"

In a blog a few weeks ago, I responded to a series of statements made by a doctor on why he/she decided to treat patients with Oncotherm over Pyrexar.  One reason, and I quote "if you Google “oncothermia” you will see plenty of published data". So I put it to a simple test using search terms in 20 peer review journals that focused on cancer.  I was called out by Dr. Andras Szazz, founder of Oncotherm and author of “Oncothermia-Principles and Practices”, and informed that the company does not use the term oncothermia in technical papers. Instead I was told that authors use the term “modulated electro-hyperthermia” (mEHT) or “nanothermia”, and that is the reason the search results were so low.  I do extend an apology to Dr. Szazz for not being aware of those terms.  So I returned to the search criteria and updated the chart below.

The original post, Data does not Lie, Oncotherm... well??, can be found here with the other claims.

Statement: Google "Oncothermia" and you will see plenty of published data that it works.

tom pantsonfireThis is very misleading. In the medical field, published data refers to peer reviewed studies published in reputable medical journals. So we did our own research and typed "oncothermia" into the search bar of the journals listed below. The results compare the number of articles referencing "hyperthermia" vs number of articles referencing "oncothermia". The data spoke.

Peer Reviewed Medical Journal  "hyperthermia"  "oncothermia" "modulated electro-hyperthermia" "nanothermia"
International Journal of Hyperthermia 1985 1 3 0
European Journal of Cancer 960 1 1 0
The Lancet 484 0 0 0
International Journal of Cancer 367 0 0 0
British Journal of Cancer 343 0 0 0
Journal of Clinical Oncology 227 0 0 0
International Journal of Oncology 153 1 1 0
Oncology Reports 132 0 1 0
The Journal of the American Medical Association 80 0 0 0
European Society of Radiotherapy and Oncology 79 0 0 0
Cancer Immunology, Immunotherapy 52 0 0 0
International Journal of Medical Science 37 0 0 0
CA: A Cancer Journal for Clinicians 33 0 0 0
Journal of the National Cancer Institute 32 0 0 0
Japanese Journal of Clinical Oncology 30 0 0 0
Prostate Cancer and Prostatic Diseases 10 0 0 0
Journal of Clinical Investigation 8 0 0 0
Cancer Medicine 7 0 0 0
Society for Endocrinology 7 0 0 0
Cancer Epidemiology, Biomarkers & Prevention 3 0 0 0
Updated Totals 5,029 3 6 0

Update: Using the new terms, data claimed by oncotherm systems added 3 additional mentions.

So don't fall for it. 17 Phase III studies show its about Heat, not Hype.

ABC News Report on Hyperthermia - Part 5

In the follow-up fifth installment of the ABC story, we see hyperthermia cancer treatment take a foothold in Utah.  Gamma West Cancer Services, serving the Intermountain West starts its own thermal oncology group.  We hear about their early success with the treatment and their plans to expand the service.  If you missed the previous Part 1Part 2Part 3Part 4 you can use the links.


Last year, ABC4 traveled to New Orleans to learn about hyperthermia: a cancer treatment that kills harmful cells with heat. We explored its use throughout the world, but found that hyperthermia was not being used in the Intermountain West.

But now, it is.

“Cancer's not a neat word for anybody,” says Terrance Faber.

Faber was diagnosed with stage four prostate cancer one year ago.

“You know, I have aggressive cancer...and whatever we can do to combat that. And hyperthermia apparently is one really big help,” Faber continues.

And now he has that option right here in Salt Lake City. Gamma West Cancer Services is the first facility in Utah to use hyperthermia treatment.

Dr. John Hayes,the president of Gamma West, says “We have invested space, equipment, personnel...and we would like to become a regional center of excellence for hyperthermia.”

Hayes explained that there is clinical data which shows a benefit when you add hyperthermia to an already prescribed radiation treatment, especially in recurrent cancers.

So, when Faber’s cancer came back, Dr. Hayes added hyperthermia to Faber’s treatment plan.

Dr. Hayes says it works like this: the heat causes more blood to flow into the tissue. That brings more oxygen to the tumor cells trapped inside scar tissue. This makes radiation more effective.

Mr. Faber has plenty of scar tissue from previous treatments.

Our crew was there for Faber’s first hyperthermia treatment.

“Because he's had prior treatment, we're going to give a treatment with extra power, and let's say umph, to get rid of all this cancer,” Dr. Hayes explains.

Hyperthermia treatments have been around for more than three decades. Just last year, we at Good4Utah showed you how it's being used in Europe. However, many facilities in the U.S. still aren't using it. Many of these places say there is not enough peer-reviewed research yet to prove, or disprove, its effectiveness.

But Dr. Hayes disagrees.

“With hyperthermia, we have decades old data, with 15 randomized controlled clinical trials showing a benefit.”

Dr. Hayes says it typically only takes a few days to see a tumor visibly shrink after being treated with hyperthermia.

Both Dr. Hayes and Mr. Faber are optimistic about the future.

“I'm real excited about the way things are going. I'm feeling real good,” says Faber.

 

Data does not Lie, Oncotherm... well??

We have recently heard a few stories from doctors who have purchased Oncotherm systems. When asked why they did not choose the industry standard, Pyrexar Medical, for their hyperthermic cancer treatment center, their answers revealed some sly misinformation.  The statements below are hearsay, and we presume that the anecdotal information was represented to physicians during the equipment sales process. We have provided statement ratings to help you separate fact from fiction.

Statement: Google "Oncothermia" and you will see plenty of published data that it works.

tom pantsonfireThis is very misleading. In the medical field, published data refers to peer reviewed studies published in reputable medical journals. So we did our own research and typed "oncothermia" into the search bar of the journals listed below. The results compare the number of articles referencing "hyperthermia" vs number of articles referencing "oncothermia". The data spoke.

Peer Reviewed Medical Journal  "hyperthermia"  "oncothermia"
International Journal of Hyperthermia 1985 1
European Journal of Cancer 960 1
The Lancet 484 0
International Journal of Cancer 367 0
British Journal of Cancer 343 0
Journal of Clinical Oncology 227 0
International Journal of Oncology 153 1
Oncology Reports 132 0
The Journal of the American Medical Association 80 0
European Society of Radiotherapy and Oncology 79 0
Cancer Immunology, Immunotherapy 52 0
International Journal of Medical Science 37 0
CA: A Cancer Journal for Clinicians 33 0
Journal of the National Cancer Institute 32 0
Japanese Journal of Clinical Oncology 30 0
Prostate Cancer and Prostatic Diseases 10 0
Journal of Clinical Investigation 8 0
Cancer Medicine 7 0
Society for Endocrinology 7 0
Cancer Epidemiology, Biomarkers & Prevention 3 0

If you go to the American Cancer Society website and type “oncothermia”... Sorry, no matches were found...  But it gets worse, type "oncothermia" into Google and among the findings, you get an NIH abstract "Current Status of Oncothermia Therapy for Lung Cancer" by Andras Szasz,PhD . The paper uses HT studies as the foundation that hyperthermia works, but then introduces oncothermia as a false equivalent. Under the Clinical Evidence section it states that no clinical results can be provided, instead just observations through case studies. Szasz is the founder of Oncotherm and is the author of the majority of the claims found on the internet.

Statement: Pyrexar is only FDA approved for Cervical cancer and superficial tumors of Melanoma and Sarcoma.

tom falseIn fact the BSD-500 Superficial/Interstitial system is approved for most indications.  It has well documented success in superficial lesions like recurrent chest wall tumors, soft tissue sarcoma and melanoma. The BSD-500 Hyperthermia System is indicated for use alone or in conjunction with radiation therapy in the palliative management of certain solid surface and subsurface malignant tumors (i.e., melanoma, squamous- or basal-cell carcinoma, adencarcinoma, or sarcoma) that are progressive or recurrent despite conventional therapy. Because its interstitial capabilities are designed for brachytherapy, it has the ability to treat along side any brachytherapy treatment. This makes the BSD-500 is a very effective system. In the U.S. the BSD-2000 is FDA HDE approved for Cervical cancer, but that restriction is changing.

Statement: Pyrexar Systems requires a temperature probe to be inserted into the tumor under imaging guidance.

tom falseThat is very old data. Although a physician could choose to place a temperature probe directly into the tumor, it would be an extremely rare case, not a common practice, aside from Brachytherapy where a catheter is already inserted into the tumor for radiation. We use that existing path for both temperature probes and rf antenna placement. Pyrexar equipment can track up to 8 temperature probes with a temperature resolution of ± .2˚C (per ESHO guidelines), and are commonly taped to the surface for superficial tumors or placed near deep tumors through the natural orifices using closed tip catheters. Physicians can easily place probes using their knowledge of physiology without the need for image guidance.

Statement: With Oncothermia you don’t need to use temperature probes.

tom mostlytrueThis is absolutely true, but for the wrong reason. Oncotherm claims that the heat component is not the therapeutic effect on the tumor, even though they continually reference hyperthermia (heat) clinical studies. The Oncotherm system is generally not capable of elevating tumor tissues to therapeutic temperature where probes would provide necessary data and system control.  Instead they promote an unsubstantiated belief that frequency waves effect the tumor at the cellular level. This is alarming as there is no clinical evidence of this “effect”. Doubly alarming is that Oncotherm is convincing physicians to use this equipment on their patients with cancer.

Statement: FDA approval is not that important unless you sell in the US.

tom mostlyfalseFDA approval is the gold standard around the world.  It is very difficult to get because it requires claims to be based on supporting factual evidence.  Even though not required for sales outside the US (there are no Oncotherm systems operating legally in the US) the global medical community acknowledges this labeling and the gravity of its certification. In addition to being Made in America, Pyrexar also has CE, TUV, ISO 13485, RoHs and KFDA approvals. (CFDA and TFDA re-certification pending due to our address change)

Statement: The recent Amsterdam study shows the radiative heating method (used by Pyrexar) was superior in heating versus all capacitive heating systems, but is not user friendly.

tom truetom falseThe study showed the radiated source heating was superior (read previous post) in the Pyrexar Superficial system but that has nothing to do with user friendly.  Pyrexar systems now come standard with a 24” monitor, a new improved applicator support arm, simple temperature thermal well sensor calibration and a redesigned user friendly touch screen interface, plus many other time saving and simplification features. The features that are most accessed by the RT are icon driven and right up front. All of the more advanced controls and treatment simulators are still active and can be easily pulled up on the screen for more advanced user adjustments.  The software tracks input from the temperature probes and continuously makes power adjustments to hold the tumor at target temperatures.

So don't fall for it. 17 Phase III studies show its about Heat, not Hype.

Study Shows Capacitve Heating the Poor Choice

New Study shows that Radiated Hyperthermia is superior to Capacitive Hyperthermia in the Treatment of Superficial Cancerous Tumors. Clinical data demonstrates that adding superficial hyperthermia treatment to radiation in the treatment of Recurrent Chest Wall Tumors (breast cancer) and malignant melanoma can double* the complete response (tumor eliminated) rate. Add Hyperthermia, Your chances of beating cancer DOUBLES!

The downside, not everyone who claims to offer hyperthermia can deliver this potentially life saving benefit.  It essential comes down to two heat delivery methodologies; Capacitive vs Radiated Electromagnetic Fields. In a recent comparison study at the Department of Radiation Oncology at the University of Amsterdam, researchers H.P. Kok and J. Crezee compare hyperthermia systems made by Pyrexar, ALBA, Oncotherm, Celcius 42 and Thermotron. SPOILER ALERT: Pyrexar’s BSD-500 Superficial Hyperthermia system is the only one among the systems tested to earn FDA Approval.

Feature Radiated Microwave Capacitive
Pyrexar Oncotherm Celcius 42 Thermotron
FDA Approved YES NO NO NO
Temperature Probes & Monitoring YES NO NO YES
SAR based tumor temp. YES NO YES YES
Phase III published clinical studies HT+RT YES NO NO NO
Made in the USA YES NO NO NO


Pyrexar uses radiated microwave / radio frequency to pass energy into the body and absorbed by the tissue as heat. This heat delivery can be measured and compared using a numerical value called a SAR (Specific Absorption Rate). Primary benefit of choosing a hyperthermia system using frequency radiated field is that the energy can be transmitted from the antenna to the cancer tumor without getting stuck in the fat layer.  Capacitive heating techniques used in Oncotherm, Celsius 42 and Thermotron have difficulty passing thru the fat layer.  This often results in the super-heating of the fat layer, causing patient discomfort and blocking the tumor from receiving a therapeutic dose of heat.

Capacitive systems often claim they heat, just not where it will do the patient the most good if there is superficial fat over the tumor.  More fatty tissue in the treatment area equals poor results.  Oncotherm claims they avoid over heating of the fat tissues of the surface by limiting the radio frequency power from their capacitive electrodes .  Technology speak for they don't heat, hoping to rely on their claimed non-thermal effects for the treatment. 

Conclusion from the report, “This study showed that radiative hyperthermia yields more favorable SAR and temperature distributions for superficial tumor locations, compared with capacitive heating, especially within heterogeneous tissues. With radiative heating, higher tumor temperatures can be achieved without inducing treatment limiting hot spots, which will benefit clinical outcome.”

View the entire report “A comparison of the heating characteristics of capacitive and radiative superficial hyperthermia” in the International Journal of Hyperthermia, 2017.

* statement based on published Phase III Clinical Studies

Join Us at the 34th Annual STM

Please join us at the 34th Annual Meeting of the Society for Thermal Medicine in Cancun, Mexico. I know some of you are still experiencing winter, so enticing you with ocean water temperatures of 81˚F would be unfair.  But supporting and participating in the advancement of the hyperthermia industry is a good thing.

This years meeting will be held April 29th thru May 2nd at the CasaMagna Marriott Cancún Resort.  The 2017 Program Chair is Robert Ivkov from the Department of Radiation Oncology at Johns Hopkins University School of Medicine.  You can register for the conference at the STM website, thermaltherapy.org. The full conference program is available here.

The conference is shaping up to feature an outstanding line-up of the world’s thought leaders and prominent researchers presenting cutting-edge developments in biology, physics, engineering, and clinical applications of thermal medicine. Our CTO, long time STM member and industry expert, Paul Turner will be in attendance.  Jason Ellsworth, our VP of Engineering, will be a featured speaker at the event. And as the company CEO, I will be available to field any questions about the direction Pyrexar is taking to expand the global market.

In addition to being an event gold sponsor, Pyrexar has invited several hyperthermia luminaries from the ESHO (European Society of Hyperthermic Oncology). Dr. Niloy Datta, Dr. Rolf Issels and Dr. Jacoba Van der Zee will be there to speak at the event and share their experiences.

 

stm cancun

The Future of Radiation Therapy in Peril

With the increased attention worldwide on immunotherapy, the future of radiation therapy as a monotherapy is at risk of losing ground as the standard of care. In order to fight radio-resistant tumor types, oncologists are reaching for treatment solutions that can close the performance gap of existing therapies to increase tumor control. Monotherapy treatments, like radiation therapy, are being pushed aside by dual-therapy treatment programs. So what can be done to increase radio sensitivity, reduce toxicity and improve outcomes?

RF hyperthermia is one such dual-therapy technology that is leading the charge. Hyperthermia is an ideal adjunct therapy for radiation resistant tumors. Focused energy applied to the tumor site (targeting tumor heating of 41 C) is a highly effective radio-sensitizer. In addition, provides this heightened benefit with little to no-toxic effect to the patient.

  • Known benefits of hyperthermia include:
  • Increased oxygenation of the tumor site.
  • Inhibits DNA repair.
  • Assist in cell death during cellular s-phase.
  • Increases in effective Gy dose by as much as 150 percent.

Phase III clinical studies have shown dramatic improvement of tumor control and long-term patient survival by adding RF hyperthermia. Targeted heating within four hours before or after radiation therapy can increase the radiosensitivity of the cancer tumor. The benefit of increased oxygenation of the tumor site can remain for up to 24 hours.

The Pyrexar family of highly reliable, deep regional and superficial/interstitial hyperthermia systems are based on 30 years of product development and tens of thousands of patient treatments. Pyrexar cancer treatment devices use radio frequency to deliver focused energy to the tumor site. This technology allows for superior heating of most soft tissue tumors, provides temperature mapping and treatment zone control, with emphasis on patient comfort.

At this year’s RSNA trade show in Chicago, Pyrexar will be introducing the next step in image guided thermal therapy, the newly redesigned BSD-2000 3D/MR. The benefit of the 3D/MR system is that it allows the oncologist and therapist to accurately visualize tumor and treatment zone temperatures using the MRI.

The new applicator, designed to fit the majority of tesla 1.5 systems, surrounds the patient’s body in the approximate area of the tumor. The patient and applicator are transported inside the MRI. The initial MRI image records the proton resonance frequency image using known baseline temperatures. As the system begins to heat the tumor area, subsequent images are taken. Software calculates the temperature dependent image changes and builds a 3-D temperature map of the tumor and surrounding tissue. Having live temperature data provides the operator easy retargeting, via control software, to ensure the tumor is within the treatment zone and has reached prescribed temperature and coverage. After treatment, applicator can be stored for normal MRI imaging workflow.

RSNA Trade Show Booth Mock-up

RSNA Chicago is approaching fast.  Our booth just shipped out this afternoon. Below are pictures of our booth mock-up we use to help use plan the event.  We are offering a sneak peak of our new BSD-2000 3D/MR Applicator at the show.  Everyone on the team has been working hard all year for this achievement. We will be sharing specifics of the product and our first installation in Germany, later this month.

If you are planning on attending the show, please stop by booth #3257 and be the first to see the new product.  For more details, visit our events page. If you would like to make an appointment with our CEO and our team, please use the form link.

Booth 1

Booth 2

Booth 3

Booth 4

Booth 5

World's Largest Hospital Supporting Hyperthermia

A high-point of the show was an impromptu presentation by Dr. Daoke Yang on the advances of hyperthermia in China.  Dr. Yang is the head of oncology for the First Affiliated Hospital of Zhengzhou University. Dr. Yang presented clinical data to support the benefits of hyperthermia as an adjunct to chemotherapy and radiotherapy. And explained in great detail, the triggered immune response when heat is applied to tumor cells.

dr yang presentation

First Affiliated Hospital of Zhengzhou University is the largest hospital in the world. With over 10,000 beds (after the hospital's latest expansion opening Q1 2017), the hospital is not only the largest in the world, but nearly three times larger than the world’s second largest hospital in Belgrade, Serbia.

zhangzhou university

A special thanks to Mrs. Wang, president of Orientech Dalian, for orchestrating the visit. We are expecting to place several Pyrexar Hyperthermia systems in ZhengZhou early next year.

Recent Blogs

The Pyrexar Blog is an Opinion Editorial written by Drew Wilkens, Vice President of Digital Content Marketing. We strive to provide factual information and rebuttal or corrections are welcome. Please send your comments to marketing@pyrexar.com